Takeda psoriasis drug outperforms deucravacitinib in phase 3 trial

September 30, 2026 1:02 AM

Takeda Pharmaceutical (TSE: 4502, NYSE: TAK) announced Phase 3 clinical trial results showing its investigational drug zasocitinib outperformed deucravacitinib in ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found